PARSPORT
PARSPORT is a phase III multi-centre randomised controlled trial of parotid sparing IMRT in patients with head and neck cancer.
Disease site: Head and neck
Treatment modality: Radiotherapy
Status: In active follow-up
Trial details
The PARSPORT trial is designed to demonstrate a difference in the proportion of patients suffering xerostomia (dry mouth) of grade 2 or more, 1 year after treatment, in head and neck cancer patients treated with parotid-sparing intensity modulated radiotherapy or conventional radiotherapy.
94 patients were recruited from January 2003 to December 2007 from 6 UK centres.
The work is supported by the NCRI CTrad Group and the NCRI Head and Neck Cancer Studies Group.
Chief Investigator: Dr Chris Nutting, The Royal Marsden NHS Foundation Trust
ICR-CTSU Scientific Lead: Dr Emma Hall
Trial management contact: Mark Sydenham - Trial Manager, [email protected]
ISRCTN: 48243537
Sponsor: The Royal Marsden NHS Foundation Trust
Funding: Cancer Research UK (CRUK/03/005)
Further information
View PARSPORT on the National Institute for Health Research website: NIHR - Be Part Of Research
Patient friendly information on the PARSPORT trial at CancerHelp UK
Publications and presentations
Buettner F, Miah AB, Gulliford SL, et al. Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. Radiother. Oncol. 2012;103(1):82-7
Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lanc. Oncol. 2011;12(2):127-36
Nutting C, Harrington K, Rogers S, Sydenham M, A'Hern R, Hall E. Results of a Phase III Multi-centre Randomised Controlled Trial of Intensity Modulated (IMRT) vs Conventional Radiotherapy (RT) in Head and Neck Cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). Clin. Oncol. 2010;22(10):899
Nutting C, J M, Sydenham M, et al. Results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03 005). Radiother. Oncol. 2010;96:S186 #495
Clark CH, Miles EA, Urbano MT, et al. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and
parotid-sparing IMRT for locally advanced head and neck cancer. Br. J. Radiol. 2009;82(979):585-94
Nutting C, A'Hern R, Rogers MS, et al. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J. Clin. Oncol. 2009;27(18S):LBA6006
Nutting CM, Rogers S, Sydenham M, et al. First results of a phase III multi-centre randomised controlled trial of Intensity Modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN 48243537; CRUK/03/005). Eur J Cancer Supplements 2009;7(3):8
Nutting C, A'Hern R, Rogers MS, Sydenham M, Adab F, Harrington K, Jefferies S, Scrase C, Yap BK, Hall E, on behalf of the PARSPORT Trial Management Group,Results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). NCRI National Cancer Conference; 2009; Birmingham.
Clark CH, Miles EA, Urbano TG, Bhide S, Bidmead M, Nutting CM. Quality Assurance for an IMRT Trial: Pre-trial Exercises for PARSPORT. Clin Oncol (R.Coll.Radiol.) 2007;19(Suppl 3):#S6
Guerrero Urbano MT, Clark CH, Kong C, et al. Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines. Clin. Oncol. (R. Coll. Radiol). 2007;19(8):604-13